Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 253

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 1
Chunk 253
---
 of eligible compensation.

Note 16. Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM or decision-making group in making decisions on how to allocate resources and assess performance. Our CODM is our CEO. Our CEO views our operations and manages our business as one operating segment, which derives its revenues from the development and commercialization of therapies for patients with rare diseases.Our CEO manages and allocates resources to the operations of our company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with our long-term company-wide strategic goals. In making these decisions, our CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on the Company’s consolidated net income (loss). Through this analysis, the CODM assesses performance by comparing actual consolidated net income (loss) versus the budget, and then decides how to allocate resources to invest in the Company’s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.

F-27

The following table contains additional information on our consolidated revenue and net income (loss), including significant segment expenses:(In thousands) Years Ended December 31:202420232022Product revenue, net$36,498 $26,823 $11,740 PK activator (PYRUKYND®) direct expenses - research and development(112,720)(101,322)(83,271)Compensation and related expenses - research and development(114,618)(108,484)(109,248)Total selling, general and administrative expenses(156,784)(119,903)(121,673)Gain on sale of contingent payments889,136 — 127,853 Milestone payment from gain on sale of oncology business200,000 — — Other segment items*(67,787)(49,202)(57,202)Net income (loss)$673,725 $(352,088)$(231,801)*Other segment items primarily include milestone revenue, cost of sales, other research and development expenses, interest income and income taxes.

F-28